Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: Data from a randomized placebo-controlled trial

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 4, 2006, Pages 845-850

  Meisner, Franz ^a   Walcher, Daniel ^a   Gizard, Florence ^b   Kapfer, Xaver ^a   Huber, Roman ^a   Noak, Anja ^a   Sunder Plassmann, Ludger ^a   Bach, Helga ^a   Haug, Cornelia ^a   Bachem, Max ^a   Stojakovic, Tatjana ^c   März, Winfried ^c   Hombach, Vinzenz ^a   Koenig, Wolfgang ^a   Staels, Bart ^b   Marx, Nikolaus ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIV LILLE   (France)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Collagen; Diabetes; Inflammation; Plaque; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AMYLOID A PROTEIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CD4 ANTIGEN; CLOPIDOGREL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; ROSIGLITAZONE; TICLOPIDINE; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ENDARTERECTOMY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ELECTIVE SURGERY; FEMALE; GLUCOSE BLOOD LEVEL; HLA SYSTEM; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; LIPID ANALYSIS; MALE; MORPHOMETRICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYMPTOMATOLOGY; VASCULITIS;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CAROTID STENOSIS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COLLAGEN; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; MALE; MIDDLE AGED; SERUM AMYLOID A PROTEIN; THIAZOLIDINEDIONES;

EID: 33646695436     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000203511.66681.7f     Document Type: Article

References (28)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
2. Cipollone F, Mezzetti A, Fazia ML, Cuccurullo C, Iezzi A, Ucchino S, Spigonardo F, Bucci M, Cuccurullo F, Prescott SM, Stafforini DM. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005;25:1665-1670.
3. Hansson GK, Jonasson L, Lojsthed B, Stemme S, Kocher O, Gabbiani G. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis. 1988;72:135-141.
4. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 2000;31:40-47.
5. Loftus IM, Naylor AR, Bell PR. Plasma MMP-9 - a marker of carotid plaque instability. Eur J Vasc Endovasc Surg. 2001;21:17-21.
6. Schoonjans K, Auwerx J. Thiazoledinediones: an update. Lancet. 2000;355:1008-1010.
7. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54:2460-2470.
8. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-1178.
9. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45:1925-1931.
10. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
11. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003;42:1757-1763.
12. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W. The antidiabetic PPARg-activator rosiglitazone reduces MMP-9 serum levels in type-2 diabetic patients with coronary artery disease. Arterioscl Thromb Vasc Biol. 2003;23:283-288.
13. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfutzner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005;111:2525-2531.
14. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.
15. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004;27:2654-2660.
16. Marx N, Wöhrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Höher M. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 2005;112:2792-2798.
17. Winkler K, Konrad T, Fullert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Wieland H, Marz W. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care. 2003;26:2588-2594.
18. Koenig W Haemostatic risk factors for cardiovascular diseases. Eur Heart J. 1998;19(suppl C):C39-C43.
19. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926-933.
20. Warner SJ, Friedman GB, Libby P. Regulation of major histocompatibility gene expression in human vascular smooth muscle cells. Arteriosclerosis. 1989;9:279-288.
21. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, Badimon JJ, O'Connor WN. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004;110:2032-2038.
22. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, März W, Hombach V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in type-2 diabetic patients with coronary artery disease. Circulation. 2003;107:1954-1957.
23. Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fievet C. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2005;25:1897-1902.
24. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:365-371.
25. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43:278-284.
26. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Haring HU, Koenig W, Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 2005;25:1804-1809.
27. Martin-Ventura JL, Blanco-Colio LM, Gomez-Hernandez A, Munoz-Garcia B, Vega M, Serrano J, Ortega L, Hernandez G, Tunon J, Egido J. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke. 2005;36:1796-1800.
28. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.